AbbVie to Acquire Aliada Therapeutics for $1.4 Billion
On October 28, AbbVie and Aliada Therapeutics announced a definitive agreement under which AbbVie will acquire Aliada. Under the terms of the agreement, AbbVie will acquire all outstanding Aliada equity for $1.4 billion in cash, subject to certain customary adjustments. Aliada Therapeutics is a biotechnology company focused on addressing delivery challenges in central nervous system (CNS) drug development. Aliada uses a novel blood-brain barrier-crossing technology to address challenging CNS diseases. Aliada’s lead investigational asset utilizing this delivery technology, ALIA-1758, is an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody in development for the treatment of... Read More »
Merck Acquires Modifi Biosciences for $30 Million
On October 23, Merck & Co., Inc., known as MSD outside the United States and Canada, announced that it acquired Modifi Biosciences for $30 million upfront. Modifi Biosciences has developed a novel class of small molecules that target cancer cells lacking expression of a key DNA repair protein called O6-methylguanine methyltransferase. It is a Yale University spinout company that was formed in 2021. Merck is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company is focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines and animal health products.... Read More »
Valerio Therapeutics Acquires Emglev Therapeutics
On September 30, Valerio Therapeutics, a Paris-based, clinical-stage biotechnology company, announced its acquisition of Emglev Therapeutics. Founded in 2023, Emglev is a biotechnology company that was established as a spin-off of Institut Curie and aims to develop immunotherapies to address unmet medical needs in oncology. It is a single-domain antibody-based therapeutics company. It is headquartered in Paris, France. Valerio Therapeutics is focused on developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response. The company is focused on bringing early-stage... Read More »
Molecular Designs Acquires Lamda Biotech
On September 25, Molecular Designs announced that it entered into an agreement to acquire Lamda Biotech. Lamda Biotech is a specialized provider of research products for application in molecular biology, functional genomics, proteomics and gene therapy. For more than 20 years, Lamda Biotech has been highly regarded for its offering of cutting-edge PCR products, RT-PCR reagents, RT-qPCR kits, Direct-PCR genotyping kits, DNA ladders, SafeStain and other protein and cell biology products. Molecular Designs is a team of doctors and scientists working to advance molecular diagnostics. It offers numerous multiplex PCR-based panels produced under GMP and ISO 13485:2016 quality... Read More »
Rafael Holdings Merges With Cyclo Therapeutics
Rafael Holdings, Inc. and Cyclo Therapeutics, Inc. announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. The companies are building on a year-long history of strategic collaboration and investment. The merger involves Rafael Holdings issuing Class B common stock to Cyclo Therapeutics shareholders, valuing Cyclo shares at $0.95 each. In addition, the cash value will take into account the funding of Cyclo’s operations by Rafael with convertible notes through closing. Cyclo Therapeutics is a clinical-stage biotechnology company that focuses on the use... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
